HON

218.3101.67%

Weekly Recap | Honeywell Tech +0.68%, consensus target above spot

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Honeywell Tech rose 0.68% this week to close at $213.99, while the S&P 500 slipped 0.27%, leaving the stock ahead of the benchmark by roughly 0.95 percentage points. The week started unevenly: Monday (28 Sep) opened higher but faded to $211.52, and Tuesday (29 Sep) touched the week’s low at $209.02. The stock then firmed, closing at $213.80 on Thursday (1 Oct) and peaking at $216.13 on Friday (2 Oct) before settling at $213.99. Week amplitude was 3.

The Week

Honeywell Tech rose 0.68% this week to close at $213.99, while the S&P 500 slipped 0.27%, leaving the stock ahead of the benchmark by roughly 0.95 percentage points. The week started unevenly: Monday (28 Sep) opened higher but faded to $211.52, and Tuesday (29 Sep) touched the week’s low at $209.02. The stock then firmed, closing at $213.80 on Thursday (1 Oct) and peaking at $216.13 on Friday (2 Oct) before settling at $213.99. Week amplitude was 3.37%, with average daily volume of about 2.07m shares, roughly 23% below the 60-day median, suggesting relatively light trading.

Key Events

The standout company item was the Kenyan refinery project. Honeywell said it will help Dangote build a large new refinery in Kenya, with the news landing on 30 Sep and one report describing it as the world’s largest single-train refinery. The same day, the company declared a Q4 2026 dividend of R$2.4172447320 per unit, payable 15 Dec. A day earlier, Honeywell Aerospace set the date for its third-quarter results release and investor call. Broader industrial-tech coverage flagged a strategic pivot where aviation stayed resilient, chip demand softened, and green momentum continued, but the company-specific thread was the refinery deal and the coming earnings calendar. No material negative filing surfaced this week.

Analyst Ratings

A total of 26 brokers cover Honeywell: 11 rate it buy, 3 overweight, 9 hold, 1 underweight, 2 no opinion, and none sell. The consensus recommendation is buy, with a consensus target of $258.22, about 20.67% above the latest price of $213.99. Target prices range from $186 to $303, a wide spread that points to real disagreement, although the overall positioning remains constructive. Among eight stocks in the industrial conglomerates group, Honeywell ranks first by analyst rating.

The Week Ahead

The coming week brings US S&P Global services PMI final and ISM non-manufacturing PMI on 5 Oct, with prior reads of 58.7 and 55.4 respectively, and the ISM figure expected at 55. If services data soften, sentiment toward industrial names could wobble. On 6 Oct the US trade balance lands, followed by EIA crude inventory data on 7 Oct, which matters for the energy chain around the refinery theme. The bigger date is 22 Oct, when Honeywell reports fiscal Q3 2026 before the open. Consensus expects EPS of $1.9646 and revenue of $5.006bn, making the print a key test for aerospace and overall momentum.

In Short

Honeywell held up in a down market this week, beating the S&P 500 by about 0.95 points, with valuation at roughly 8.25x P/E and 3.66x P/B, a moderate zone. Broker consensus is buy, and the consensus target sits about 20.67% above spot. But the latest session’s money flow points to large-lot net selling while small and medium lots are net buyers, a sign of growing divergence. The next reads are services PMIs and crude inventories early next week, then the 22 Oct earnings report, which will test the aerospace story. The direction is not settled yet; the market is sensitive to the mix of upcoming data and company results.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.

Source: Weekly Review The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.